Managed Account Advisors’s Novavax NVAX Stock Holding History

Managed Account Advisors’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	$6K	Sell	28 -8	-22%	-$1.41K	﹤0.01%	2929
2015 Q1	$6K	Sell	36 -30	-45%	-$4.87K	﹤0.01%	2866
2014 Q4	$8K	Buy	66 +18	+38%	+$1.88K	﹤0.01%	2641
2014 Q3	$4K	Sell	48 -40	-45%	-$3.62K	﹤0.01%	2637
2014 Q2	$8K	Buy	88 +22	+33%	+$1.93K	﹤0.01%	2588
2014 Q1	$6K	Sell	66 -13	-16%	-$1.45K	﹤0.01%	2569
2013 Q4	$8K	Buy	+79	New	+$5.58K	﹤0.01%	2504

Other funds holding NVAX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Managed Account Advisors's NVAX Position: Q2 2015 in Review

Managed Account Advisors reduced its Novavax (NVAX) stake by 22% in Q2 2015, selling an estimated $1.41K and leaving 28 shares worth $6K. The position accounts for ﹤0.01% of the portfolio, ranked #2929.

Managed Account Advisors first reported a position in NVAX in Q4 2013 and has held it in 7 quarters since. The position peaked at $8K in Q4 2014. 159 funds tracked by Wall St. Rank hold NVAX as of Q2 2015.

Managed Account Advisors held 28 shares of Novavax worth $6K as of Q2 2015.
Managed Account Advisors sold 8 Novavax shares in Q2 2015, an estimated $1.41K.
Novavax made up ﹤0.01% of Managed Account Advisors's portfolio in Q2 2015, its #2929 holding.
Managed Account Advisors first reported a position in Novavax in Q4 2013 and has held it in 7 quarters since.
Managed Account Advisors's Novavax position peaked at $8K in Q4 2014.
159 funds tracked by Wall St. Rank held Novavax as of Q2 2015.

Based on Managed Account Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.